Google
MGNX — MACROGENICS INC (Healthcare >> Biotechnology)
MGNX FAQ
What is MGNX's P/E ratio?
MACROGENICS INC (MGNX) currently trades at a P/E ratio of 16.06.
What is MGNX's ROE?
MACROGENICS INC reports a Return on Equity (ROE) of -331.91%.
What is MGNX's dividend yield?
MACROGENICS INC offers a dividend yield of 0.00%.
What is MGNX's Deepscope Quality Score?
Deepscope rates MGNX's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy MGNX?
Deepscope's AI Timing Score for MGNX is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does MGNX belong to?
MACROGENICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 3.91
Price
-0.34
(-8.00%)
Day Change
|
|
|---|
MGNX, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.91 |
| PBV / Sector |
12.74 / 4.63
|
| Earning Per Share | -1.02 |
| PE / Sector |
16.06 / 17.43
|
| PEG or PE/Growth / Sector |
0.09 / 0.53
GREAT
|
| Average 1M Daily Value |
5.87 M
GREAT
|
| Average 1W Daily Value |
2.27 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
60% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:09:03 |
| Symbol | MGNX |
| Name | MACROGENICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 63.56 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 270.14 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 9704 Medical Center Drive, Rockville, MD, United States, 20850
Phone: 301 251 5172
Website: https://www.macrogenics.com
Employees: 293
Sector: Healthcare >> Biotechnology
Description: MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
